Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.
As of February 3th 2017, MIRN looks to be bullish, for a 1 to 4 week hold. A purchase at a price between $2.15 and $2.32 is safe and could bring you returns between 25% and 40%% in the next 30 days. If MIRN breaks out above $2.35, we could see if reaching the $3.14++ level within the same week.
Be sure you place a stop loss at 10% below you buy price, and don’t be greedy, a consistent 10% to 15% per month can help dealing with losses and sometimes help bring in more profits.
Also, please keep in mind we are not offer trading advice, we are just sharing an idea.
For real stock trading advice you should contact a professional financial adviser.